(NASDAQ: CTMX) Cytomx Therapeutics's forecast annual revenue growth rate of -31.39% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.61%.
Cytomx Therapeutics's revenue in 2025 is $113,631,000.On average, 10 Wall Street analysts forecast CTMX's revenue for 2025 to be $14,470,968,781, with the lowest CTMX revenue forecast at $13,206,980,734, and the highest CTMX revenue forecast at $16,107,714,696. On average, 10 Wall Street analysts forecast CTMX's revenue for 2026 to be $7,132,213,517, with the lowest CTMX revenue forecast at $664,186,748, and the highest CTMX revenue forecast at $18,146,530,805.
In 2027, CTMX is forecast to generate $8,053,603,195 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $19,925,602,452.